Open AccessP103: Comparison of PET‐derived parameters in program cell death‐1 inhibitor and CD30 antibody drug conjugate‐based therapies in patients with advanced stage cHL: A single center experience.
Author(s) -
Kamel Serageldin,
Martiniova Lucia,
Aboismail Eslam,
Schmidt Joo,
Ahmed Sairah,
Nair Ranjit,
Steiner Raphael E.,
Wang Michael L.,
Soebianto Sarita,
Ravizzini Gregory,
Pan Tinsu,
Lee Hun Ju
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890980.06633.66
Subject(s) - medicine , nivolumab , brentuximab vedotin , nuclear medicine , oncology , antibody drug conjugate , stage (stratigraphy) , antibody , immunotherapy , cancer , lymphoma , hodgkin lymphoma , immunology , monoclonal antibody , paleontology , biology